In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GSK market cap is currently £55.9B and has a P/E ratio of 22.22. Based on the recent corporate insider activity of 333 insiders, corporate insider sentiment is positive on the stock. This means that ...

Several companies such as Shriram Finance, Symphony, etc. will be in focus today on account of corporate actions.

GSK bought into the EOS-448 programme last year in a deal orchestrated by its chief scientific officer Hal Barron, who is leaving to join biotech startup Altos at the beginning of August.

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a ...

The highest price of Glaxosmithkline Pharmaceuticals Ltd stock is ₹3,088.00 in the last 52-week. What is the share price of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) today on NSE? As on Nov 08 ...